Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis
Authors:
- 21 July 2003
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (1) , CD003570
Abstract
Background Allergic rhinitis and asthma are mediated by similar allergic mechanisms. They may represent two manifestations of the same united airway disease and therefore intranasal corticosteroids (INCS) could improve asthma. Nevertheless none of the asthma guidelines have advocated intranasal corticosteroids for asthma. Objectives To assess the efficacy of intranasal corticosteroids on asthma outcomes in people with rhinitis and asthma. Search methods We searched the Cochrane Airways Group trials register, the Cochrane Central Register of Controlled Trials (Issue 1, 2003), MEDLINE and reference lists of articles. We also contacted researchers in the field. The last search was conducted in March 2004. Selection criteria Randomised controlled trials comparing intranasal corticosteroids to intranasal placebo or to other traditional asthma treatments were included. Intrabronchial corticosteroids were not allowed but a device combining intranasal and intrabronchial corticosteroid was considered as being a primary INCS technique and was therefore also compared to placebo. Data collection and analysis Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for additional information. Quality assessment for the 14 eligible studies was performed using the Jadad score and by ranking allocation concealment. Statistical analysis for continuous data was done by weighted mean difference or standardised mean difference. Main results Fourteen trials involving 477 people were included. Meta‐analysis for asthma outcomes failed to show a statistically significant benefit of INCS in asthma. However, for symptom scores and forced expiratory volume in one second, the trend favoured a beneficial effect of INCS. For asthma symptom scores (two parallel studies), the standardised mean difference was 0.61 (95% confidence interval (CI) ‐0.04 to 1.26). Meta‐analysis for forced expiratory volume in one second (five parallel studies) gave a standardised mean difference of 0.31 (95% CI ‐0.04 to 0.65). In the parallel studies, meta‐analysis of peak expiratory flow gave a standardised mean difference of ‐0.10 Litres/min (95% CI ‐0.55 to 0.35) for mean peak flow (three studies). Meta‐analysis for methacholine airway responsiveness (three parallel studies) showed a standardised mean difference of ‐0.20 (‐95% CI 0.64 to 0.24). Authors' conclusions Intranasal corticosteroids were well tolerated. While INCS tended to improve asthma symptoms and forced expiratory volume in one second, the results did not reach significance. The combination of intranasal plus intrabronchial corticosteroids should remain the current clinical practice until more research is done.Keywords
This publication has 29 references indexed in Scilit:
- The health economics of asthma and rhinitis. I. Assessing the economic impactJournal of Allergy and Clinical Immunology, 2001
- Influence of intranasal steroids during the grass pollen season on bronchial responsiveness in children and young adults with asthma and hay feverThorax, 2000
- Subjective and objective markers of treatment response in patients with seasonal allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2000
- Other anti‐inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseasesAllergy, 2000
- Six-week trial of nebulized flunisolide nasal spray: Efficacy in young children with moderately severe asthmaPediatric Pulmonology, 1997
- Overview of comorbid associations of allergic rhinitisJournal of Allergy and Clinical Immunology, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Investigation of the tendency to wheeze in pollen sensitive patientsClinical & Experimental Allergy, 1992
- Nasal inhalation of the glucocorticoid budesonide from a spacer for the treatment of patients with pollen rhinitis and asthmaAllergy, 1990
- Effects of topical nasal treatment on asthma symptomsJournal of Allergy and Clinical Immunology, 1988